Search Result

Search Result

Isoforms Recommended:	Blk

Results for "

BLK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (1) Bcr-Abl (2) BMX Kinase (1) Btk (6) CDK (1) Cyclin G-associated Kinase (GAK) (1) EGFR (4) Ferroptosis (1) FGFR (1) IRAK (2) JAK (1) LIM Kinase (LIMK) (1) MAP4K (1) MAPKAPK2 (MK2) (1) PDGFR (1) PROTACs (1) Salt-inducible Kinase (SIK) (1) Small Interfering RNA (siRNA) (1) Src (2) ULK (1)
By Research Areas:	Cancer (13) Inflammation/Immunology (1)

18

Inhibitors & Agonists

1

Peptides

2

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

BLK-IN-2	Btk	Cancer
BLK-IN-2 (compound 25) is a potent and selective irreversible inhibitor of B-Lymphoid tyrosine kinase (BLK), with an IC₅₀ of 5.9 nM. BLK-IN-2 also inhibits BTK (IC₅₀=202.0 nM). BLK-IN-2 shows potent antiproliferative activities against several lymphoma cells .

BLK degrader 1	Others	Cancer
BLK degrader 1 (compound 9) is a selective degrader of B-lymphoid tyrosine kinase (BLK). BLK degrader 1 shows anticancer activity in several B-lymphoid cell lines .

Saracatinib difumarate Maximum Cited Publications 27 Publications Verification AZD0530 difumarate	Src	Cancer
Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .

BLK-IN-1	Btk	Cancer
BLK-IN-1 (compound 1) is a selective and covalent inhibitor of B-Lymphoid tyrosine kinase (BLK) and BTK, with IC₅₀s of 18.8 nM and 20.5 nM, respectively. BLK-IN-1 can be used for the research of cancer .

BLK Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
BLK Human Pre-designed siRNA Set A contains three designed siRNAs for BLK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

BLK Human Pre-designed siRNA Set A BLK Human Pre-designed siRNA Set A

Saracatinib Maximum Cited Publications 27 Publications Verification AZD0530	Src Autophagy	Cancer
Saracatinib (AZD0530) is a potent Src family inhibitor with IC₅₀s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and *Blk*. Saracatinib shows high selectivity over other tyrosine kinases .

Tuxobertinib BDTX-189	EGFR	Cancer
Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows K_Ds of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity .

BMS-986143	Btk	Inflammation/Immunology
BMS-986143 is an orally active, reversible BTK inhibitor with an IC₅₀ of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC₅₀s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases .

ZNL0325	Others	Others
ZNL0325 is a covalent probe based on pyrazolopyrimidine. ZNL0325 features an acrylamide side chain at the C3 position, which is capable of forming covalent bonds with multiple kinases that possess a cysteine at the αD-1 position, including BTK, EGFR, BLK, and JAK3. ZNL0325 can be used in the research of creating structurally distinct covalent kinase inhibitors .

BMX-IN-1 4 Publications Verification BMX kinase inhibitor	Btk BMX Kinase	Cancer
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys ⁴⁹⁶ in the BMX ATP binding domain with an IC₅₀ of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

JAK3-IN-1	JAK	Cancer
JAK3-IN-1 is a potent, selective and orally active JAK3 inhibitor with an IC₅₀ of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for JAK3 than JAK1 (IC₅₀ of 896 nM) and JAK2 (IC₅₀ of 1050 nM) .

Larotinib mesylate hydrate	EGFR IRAK Btk	Cancer
Larotinib mesylate hydrate is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC₅₀ of 0.6 nM .

HY-153110

Larotinib

EGFR IRAK Btk Cancer

Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC₅₀ of 0.6 nM .

TAS0728	EGFR	Cancer
TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC₅₀ of 13 nM. TAS0728 also shows IC₅₀s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for *BMX、HER4、BLK、EGFR、JAK3、SLK* and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2HER3, and downstream effectors .

FIIN-1 FGFR irreversible inhibitor-1	FGFR	Cancer
FIIN-1 is a potent, irreversible, selective FGFR inhibitor. FIIN-1 binds to FGFR1/2/3/4 and Flt1/4 with K_ds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC₅₀s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively .

CHMFL-ABL/KIT-155 CHMFL-ABL-KIT-155
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC₅₀s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC₅₀=81 nM), CSF1R (IC₅₀=227 nM), DDR1 (IC₅₀=116 nM), DDR2 (IC₅₀=325 nM), LCK (IC₅₀=12 nM) and PDGFRβ (IC₅₀=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis .

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies . S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

DB1113	PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK)	Others
DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .

Species:	Human (2)
Tag:	His (1) GST (1)
Source:	Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

	BLK Protein, Human (His) rHuTyrosine-protein kinase BLK/BLK, His; Tyrosine-Protein Kinase BLK; B Lymphocyte Kinase; p55-BLK; BLK	Human	E. coli
	The BLK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signal transduction. It regulates pro-B to pre-B transition, growth arrest, and apoptosis downstream of B cell receptors by binding and phosphorylating CD79A and CD79B. BLK Protein, Human (His) is the recombinant human-derived BLK protein, expressed by E. coli , with C-6*His labeled tag. The total length of BLK Protein, Human (His) is 504 a.a., with molecular weight of ~60.0 kDa.

	BLK Protein, Human (sf9, GST) Tyrosine-protein kinase BLK; B lymphocyte kinase; p55-BLK; BLK	Human	Sf9 insect cells
	The BLK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signal transduction. It regulates pro-B to pre-B transition, growth arrest, and apoptosis downstream of B cell receptors by binding and phosphorylating CD79A and CD79B. BLK Protein, Human (sf9, GST) is the recombinant human-derived BLK protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of BLK Protein, Human (sf9, GST) is 505 a.a., with molecular weight of ~84 kDa.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us